Mdxhealth S.A. Reports Strong Q3 Growth and Strategic Acquisition

Mdxhealth S.A. ( (MDXH) ) has released its Q3 earnings. Here is a breakdown of the information Mdxhealth S.A. presented to its investors.

Mdxhealth S.A. is a precision diagnostics company specializing in molecular information for personalized patient diagnosis and treatment, primarily focusing on prostate cancer and other urologic diseases. In its latest earnings report, Mdxhealth announced an 18% increase in Q3 revenues, reaching $27.4 million, and reported an adjusted EBITDA profitability of $1.0 million. The company also highlighted its strategic acquisition of Exosome Diagnostics from Bio-Techne Corporation, which is expected to enhance its product offerings and sales capabilities.

The financial performance of Mdxhealth in the third quarter of 2025 showed significant improvements, with a gross margin increase to 65.2% and a net loss reduction of 28% compared to the previous year. The company also reported a 65% increase in liquid-based test volumes, showcasing strong demand for its diagnostic solutions. The acquisition of Exosome Diagnostics is a key strategic move, expanding Mdxhealth’s sales team and offering cross-selling opportunities with its existing product lines.

Despite the suspension of its germline product introduction, Mdxhealth remains optimistic about its financial outlook, reaffirming its full-year revenue guidance of $108 million to $110 million. The company aims to capitalize on the integration of Exosome Diagnostics and anticipates continued revenue growth exceeding 20% for the fourth quarter and the full year.

Looking ahead, Mdxhealth’s management is focused on the successful integration of Exosome Diagnostics and maximizing cross-selling opportunities. The company is poised to leverage its expanded sales force and product portfolio to drive further growth and maintain its position as a leader in precision diagnostics.